Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)
Others
Ratios

Viking Therapeutics (VKTX) Income towards Parent Company: 2014-2025

Historic Income towards Parent Company for Viking Therapeutics (VKTX) over the last 12 years, with Sep 2025 value amounting to -$90.8 million.

  • Viking Therapeutics' Income towards Parent Company fell 262.79% to -$90.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$237.3 million, marking a year-over-year decrease of 139.32%. This contributed to the annual value of -$110.0 million for FY2024, which is 28.17% down from last year.
  • Per Viking Therapeutics' latest filing, its Income towards Parent Company stood at -$90.8 million for Q3 2025, which was down 38.52% from -$65.5 million recorded in Q2 2025.
  • Viking Therapeutics' 5-year Income towards Parent Company high stood at -$12.4 million for Q4 2021, and its period low was -$90.8 million during Q3 2025.
  • Over the past 3 years, Viking Therapeutics' median Income towards Parent Company value was -$25.0 million (recorded in 2024), while the average stood at -$36.2 million.
  • Data for Viking Therapeutics' Income towards Parent Company shows a maximum YoY plummeted of 262.79% (in 2025) over the last 5 years.
  • Quarterly analysis of 5 years shows Viking Therapeutics' Income towards Parent Company stood at -$12.4 million in 2021, then plummeted by 58.29% to -$19.6 million in 2022, then decreased by 25.72% to -$24.6 million in 2023, then slumped by 44.00% to -$35.4 million in 2024, then tumbled by 262.79% to -$90.8 million in 2025.
  • Its last three reported values are -$90.8 million in Q3 2025, -$65.5 million for Q2 2025, and -$45.6 million during Q1 2025.